BOEHRINGER-INGELHEIM
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
True Announces New Investment Partnership with Integrum to Redefine the Future of the Executive Talent Industry18.11.2025 16:33:00 CET | Press release
True, the premier global executive talent platform driving the industry’s tech evolution through data, AI, and expertise, today announced a new strategic investment partnership with Integrum Holdings LP (“Integrum”), a private investment firm focused on partnering with tech-enabled professional services companies. Integrum’s significant investment will power True’s next phase of growth as it helps clients solve their most pressing talent and leadership needs. Since its founding over 12 years ago, True has become a disruptive force in the industry, growing from a boutique into the sixth-largest executive search firm in North America with over $350 million in revenue. True’s organic growth has been fueled by its highly talented professionals and culture of innovation. With a tech-first and entrepreneurial mindset, and focus on transparency, True has reshaped the executive talent landscape. Brad Stadler, co-founder and CEO of True, said, “I knew during our first meeting, the group at Inte
Klarna now available on Apple Pay in Denmark, Spain, and Sweden with France to follow18.11.2025 16:22:00 CET | Press release
3 countries join the U.S., Canada, and UK in offering the ability to pay with installments when checking out online and in person with Apple Pay Klarna, the global digital bank and flexible payments provider, announced today that its flexible payment products are now available when checking out on Apple Pay in Denmark, Spain, Sweden. The launch brings even greater flexibility and transparency to Apple Pay customers in these countries, with Klarna available to eligible users checking out online and in-app with an iPhone or iPad, and in-store on an iPhone. The expansion builds on successful launches of this feature in the US, UK and Canada, where millions of customers have checked out with Klarna through Apple Pay. Klarna is one of the first buy now, pay later providers to be available on Apple Pay in these countries, offering consumers a seamless, flexible way to pay. Customers in France will be able to check out with Klarna on Apple Pay in the coming weeks. “After the fantastic respons
Bitfury Launches $1 Billion Initiative to Advance Ethical Emerging Technologies18.11.2025 16:11:00 CET | Press release
The company will begin deploying funds as early as Q4 2025 Today, Bitcoin miner turned technology incubator Bitfury announced its pivot to an investment firm with the launch of its $1 billion funding initiative, which seeks to back a new generation of ethical innovators. The firm’s new mission is to close the gap between the accelerating pace of technological progress and the slower evolution of ethical development — a disconnect it sees as a root cause of many global challenges. By supporting mission-driven founders, the company seeks to accelerate ventures that embed ethics, transparency, and human values at the core of emerging technologies. Bitfury’s new chapter as an investment firm builds on its pioneering legacy while expanding its role from technology provider to global catalyst for responsible innovation — ensuring the digital economy develops with integrity and long-term sustainability. Bitfury was originally founded in 2011 as a bitcoin miner, but over the past 15 years has
Interactive Brokers Expands Global Market Access with the Taipei Exchange18.11.2025 16:00:00 CET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced access to the Taipei Exchange (TPEx), further expanding its global reach. Eligible clients of Interactive Brokers can now trade equities, ETFs, and Taiwan Depositary Receipts (TDRs) listed on TPEx, alongside products from over 160 global exchanges from a single platform. This extends the opportunity set available to global investors seeking Asian exposure, including the growth potential afforded by emerging small and medium-sized companies listed on the TPEx. Interactive Brokers is one of the few global trading platforms connected to TPEx, a leading Asian exchange for shares of small and medium-sized enterprises (SMEs). Through TPEx, clients can diversify their portfolios to include emerging, high-tech, and creative industries, as well as SMEs and micro-enterprises across Taiwan’s developing economy. To simplify trading, Interactive Brokers will facilitate TPEx trades with an automatic FX conversion be
Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 15:00:00 CET | Press release
New release brings predictive intelligence, regional expansion, and enhanced employee performance tools to contact center operations. Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom